Unleash Prosperity economist Tomas Philipson argues lengthy FDA approval timelines are delaying lifesaving treatments and calls for a COVID-era "Operation Warp Speed" model to accelerate patient access to new medicines. Cutting just one year from the Food and Drug Administration's drug review process could create more than $10 trillion in economic value while getting lifesaving medicines to patients faster, according to a new report calling for major FDA reforms. The report, The Multi-Trillion Dollar Opportunity in Reforming the FDA, published by the free-market policy group Unleash Prosperity, argues that lengthy effectiveness reviews, not safety testing, account for much of the…